Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [NCT05171647] study showing Lunsumio® (mosunetuzumab-axgb) administered subcutaneo ...

Genentech will close its cancer immunology research department, and unit head and renowned cell biologist Ira Mellman, who has been with the company for 17 years, will depart in the coming months.

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those with relapsed or refractory large B-cell lymphoma (LBCL) who are ineligible ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

SOUTH SAN FRANCISCO, Calif., January 28, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the overall survival (OS) analysis ...

Genentech, a leading biotechnology company, recently announced the permanent closing of their Cancer Immunology Department. This announcement comes as a major surprise in the scientific community.

Genentech previously said the use of the drug in the indication accounts for a fraction of its overall revenue from Gavreto in the United States, according to Blueprint. News.

Genentech’s chief diversity office (CDO), created in 2020, has set the goal of doubling Black and Latinx representation among directors and extended leadership.

Genentech has received Food and Drug Administration approval for its treatment of certain types of lung, liver, skin and soft tissue cancer in adults. The treatment, called Tecentriq Hybreza, can ...

Genentech announced that new data were presented at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria. Highlights included presentations from ...

Genentech’s latest manufacturing expansion is one among the many investments into US-based manufacturing operations to counter international tariffs, national security concerns, rising tensions with ...